Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Approves Jardiance for Patients with Type 2 Diabetes and Cardiovascular Disease

XTALKS VITALS NEWS

FDA

The drug can now be prescribed to reduce the risk of cardiovascular death, due to events like heart attack and stroke, in patients with type 2 diabetes.

Share this!

December 6, 2016 | by Sarah Hand, M.Sc.

In light of new evidence, the US Food and Drug Administration (FDA) has approved a new indication for Boehringer Ingelheim’s cardiovascular drug, Jardiance. The drug can now be prescribed to reduce the risk of cardiovascular death, due to events like heart attack and stroke, in patients with type 2 diabetes.

“Cardiovascular disease is a leading cause of death in adults with type 2 diabetes mellitus,” said Dr. Jean-Marc Guettier, director of the Division of Metabolism and Endocrinology Products in FDA's Center for Drug Evaluation and Research. “Availability of anti-diabetes therapies that can help people live longer by reducing the risk of cardiovascular death is an important advance for adults with type 2 diabetes.”

Adult patients with diabetes face a 70 percent increased risk of death from cardiovascular disease, according to statistics from the Centers for Disease Control and Prevention (CDC). Compared to people without diabetes, these patients have a shortened life expectancy.



Jardiance was originally approved by the FDA in 2014 to help patients with type 2 diabetes better manage their blood sugar. The drug’s original indication allowed it to be prescribed alongside changes in diet and exercise.

Based on the results of a postmarketing clinical trial conducted by Boehringer Ingelheim, Jardiance’s list of indications was expanded. The study – which involved 7,000 patients with comorbid type 2 diabetes and cardiovascular disease – found that Jardiance reduced the risk of cardiovascular death, compared to a placebo.

While the new FDA-approved indication is a win for Boehringer Ingelheim, the approval comes with some restrictions. Jardiance must be used in conjunction with medications used to manage diabetes, as well as therapies meant to control atherosclerotic cardiovascular disease.


Keywords: FDA, Type 2 Diabetes, Cardiovascular Disease


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New Self-Injectable Form of Lupus Drug Approved by the FDA

July 25, 2017 - Patients with systemic lupus erythematosus (SLE) will now have the option to self-inject their medication thanks to the FDA approval of GSK’s reformulated lupus drug, Benlysta (belimumab).

Featured In: Biotech News


Canadian Chicken Farmers to Further Reduce Use of Antibiotics

July 24, 2017 - The Chicken Farmers of Canada, a national group dedicated to supporting poultry farmers and helping them meet consumer demand for chicken, has announced their strategy for eliminating the use of certain antimicrobials in meat production.

Featured In: Food News


Neonatal MRI Medical Device Approved by the FDA

July 24, 2017 - Medical device maker Aspect Imaging has received US Food and Drug Administration (FDA) approval for its Embrace Neonatal MRI System.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.